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In this issue of Chemistry & Biology, Antal and colleagues describe how phosphorylation optimizes the
signaling range of protein kinase C (PKC) isoforms. Priming of these enzymes regulates intramolecular
conformational changes, which reduces access to their diacylglycerol (DAG) binding C1 domains.Signaling networks make use of diverse
protein modules to communicate signals
throughout the cell (Pawson, 2007). A
classic example of a multiple module
enzyme that mediates various signaling
events is the protein kinase C (PKC) family
of serine/threonine kinases (Newton,
2010). PKCs regulate diverse cellular
processes such as cell growth and differ-
entiation, apoptosis, and learning and
memory. There is still a dearth of knowl-
edge on the molecular forces that regu-
late PKC conformational dynamics and
how optimal signaling is tuned. These
are important questions to answer,
because dysregulation of PKCs can lead
to diseases including cancer, diabetes,
and neurodegeneration.
The PKC isozymes are separated into
three groups based upon the architec-
ture of their membrane-binding domains
(Newton, 2010) (Figure 1A). All isozymes
have a C-terminal kinase domain, a
conserved C-terminal tail sequence that
is primed by phosphorylation, and an
autoinhibitory pseudosubstrate in the
N-terminal region. The pseudosubstrate
engages the substrate-binding cleft
keeping PKC in an inactive state until
DAG binding displaces the inhibition.
cPKCs include the a, b, and g isozymes,
which harbor N-terminal tandem C1
domains and a C2 domain that binds
Ca2+, phosphatidylserine, and phosphoi-
nositides. nPKCs comprise d, ε, h, and q
isoforms, which have tandem C1 do-
mains and C2 domains that lack high
membrane affinity (Cho and Stahelin,
2006) but can engage phosphotyrosine
on target proteins (Benes et al., 2005).
Atypical PKCs z and i/l do not
respond to Ca2+ or DAG and undergo
protein-protein interactions that regulatecellular function and localization (Kaza-
nietz et al., 1994).
PKCs mature into an active form by a
series of phosphorylation events (Newton
2010). Prior to posttranslational modifica-
tion, newly synthesized PKC ismembrane
associated (Sonnenburg et al., 2001) but
harbors a substrate-binding cleft void of
pseudosubstrate (Dutil and Newton,
2000). In absence of phosphorylation,
PKC is inactive even in the DAG mem-
brane-bound form (Sonnenburg et al.,
2001). Three tightly regulated phosphory-
lation events of the activation loop, turn
motif, and hydrophobic motif are required
for optimal PKC catalytic activity (Newton,
2010). Strikingly, the mature PKC is
autoinhibited and cytosolic, whereas
intramolecular conformational dynamics
have changed to restrict PKC DAG and
membrane affinity.
A large focus of PKC research over the
last two decades has investigated howC1
and C2 domains mediate membrane
recruitment and subsequent activation of
these enzymes. Some of the key ques-
tions in the field have been the mecha-
nism behind formation of intramolecular
interactions and how restriction of C1
domain DAG binding occurs. PKC C1 do-
mains (Figure 1B) harbor a DAG-binding
pocket that is surrounded by several hy-
drophobic residues. Isolated C1 domains
bind membranes with and without DAG
while full-length PKCs that are mature
have a lower affinity for DAG containing
membranes. Because cPKCs and nPKCs
contain two C1 domains (C1A and C1B),
studies have investigated which domain
is the predominant membrane-binding
unit or which domain becomes more
restricted in the mature form. Some
answers to these questions were recentlyChemistry & Biology 21, April 24, 2014provided in the X-ray structure of PKCbII,
which revealed that the C1B domain acts
as a clamp to restrict PKC activity prior to
membrane binding (Leonard et al., 2011).
However, crystallography of full-length or
multimodular PKC structures has been
difficult, especially when considering the
multiple conformations that would need
to be elucidated at different stages of
the maturation cycle. Thus, how PKC
isozymes are optimally driven toward
different levels of DAG has not been well
established.
In this issue of Chemistry & Biology,
several significant questions on PKC
regulation and the fine-tuning of C1
domain membrane binding have been
answered. Antal et al. (2014) first observed
that fluorescently tagged kinase-dead
mutations of PKCbII more rapidly translo-
cated to the plasma membrane in
response to phorbol dibutyrate, a PKC
agonist. To this end, they employed a
number of mutations that alter PKCmatu-
ration and prevent catalytic competence.
In addition to responding more quickly to
agonist, these mutations were also
moderately localized to plasma mem-
brane prior to agonist addition, strongly
suggesting higher membrane affinity
than mature wild-type (WT) PKC. The
phosphorylation state also wasn’t directly
correlated with the response rate to
agonist addition, because WT and one
kinase dead mutation (D466N, which is
the catalytic base in the phosphorylation
reaction) had comparable levels of phos-
phorylation. Instead, the phosphorylation
order and conformational transitions are
important and cannot be mimicked in the
catalytically inactive form.
To dig deeper into the mechanism of
PKC conformational dynamics, Newtonª2014 Elsevier Ltd All rights reserved 433
Figure 1. PKC Architecture and Conformational Dynamics
(A) The architecture of cPKCs and nPKCs is shown. cPKCs have an N-terminal autoinhibitory pseudosub-
strate (PS) followed by the C1A and C1B domains. Between the tandem C1 domains and catalytic domain
lies the Ca2+- and membrane-binding C2 domain. The kinase and C-terminal tail region harbor phosphor-
ylation sites that include (from N to C terminus) the activation loop, turn motif, and hydrophobic motif
(Newton, 2010). Phosphorylation of these sites primes PKC for catalytic activity.
(B) The C1B domain of PKCd is shown in complex with phorbol-13-acetate (red) (Protein Data Bank ID:
1PTR). Two zinc ions required for structural stability are shown in magenta. For PKCbII, Newton and
colleagues demonstrate that the C1B domain is dominant in the mature form.
(C) PKCmaturation induces conformational changes that restrict C1 domain membrane and DAG binding.
In newly synthesized PKC, the C1A and C1B domains are exposed and promote high membrane affinity.
However, in the absence of phosphorylation, the enzyme is not active. Maturation via phosphorylation
restricts the C1 domain accessibility in full-length PKC, leading to optimal sensing of DAG levels. In mature
and membrane bound cPKC, the C2 domain is engaged in Ca2+-dependent interactions with phosphati-
dylserine and PI(4,5)P2 while the C1 domains bind DAG. DAG binding induces release of the autoinhibitory
pseudosubstrate promoting PKC activation.
(A) and (C) were adapted from Antal et al.( 2014).
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Previewsand colleagues generated several new
PKC constructs for live cell imaging (Antal
et al., 2014). A FRET-based reporter was
engineered to monitor PKC conforma-
tional transitions under various cellular
conditions. A CFP was encoded at the N
terminus of PKC while YFP was intro-
duced at the PKC C terminus. This
construct was called Kinameleon and
undergoes FRET when CFP and YFP are
in close proximity. Essentially, in the un-
primed PKC, the CFP and YFP are farther
apart as PKCsmodular domains are liber-
ated, yielding a low level of FRET. As PKC
maturation ensues, FRET increases as
phosphorylation induces conformational
rearrangement of the N- and C-terminal
regions of PKC, bringing the CFP and
YFP in close proximity. Although a large
portion of the work was done with PKCbII
constructs, the authors also generated434 Chemistry & Biology 21, April 24, 2014 ªseveral constructs in the a and d iso-
zymes, revealing that PKC maturation is
likely a global mechanism regulating
PKC conformational changes and sensi-
tivity to DAG.
To investigate if C1A and C1B domains
are exposed or masked in primed and un-
primed PKCs, the authors generated
several constructs to study full-length
PKC and the isolated tandem C1 do-
mains. They also asked the question,
which C1 domain predominates in mem-
brane binding? Newly synthesized PKC
has exposed C1A and C1B domains prior
to phosphorylation, which explains the
higher membrane affinity, prelocalization
at membranes, and rapid response upon
agonist addition. Priming phosphorylation
then acts to mask both C1A and C1B do-
mains through intramolecular interac-
tions. Although both of these C1 domains2014 Elsevier Ltd All rights reservedcontribute to membrane binding of
PKCbII, the C1B plays a dominant role.
The restriction of C1 domains in mature
PKC allows for high sensitivity to small
changes in DAG levels, providing different
PKC isoforms ameans to respond to DAG
signals based upon their C1 and C2
domain architecture.
Interestingly, Newton and colleagues
(Antal et al., 2014) demonstrate that PKC
undergoes conformational changes dur-
ing the maturation process in live cells.
They have also answered several burning
questions regarding C1 domain accessi-
bility and PKC membrane interactions.
This innovative and high impact work
should redefine the way we view PKC
regulation and response to different ago-
nists. These studies are also critical to
our understanding of how to pharmaco-
logically target this important class of en-
zymes (Blumberg et al., 2008). What the
precise intramolecular interactions that
occur in different PKC isoforms are still
unknown and may include C2-C1, C1-
C1, and C1-C terminus interactions.
Nonetheless, these details can now be
investigated using the tools Newton and
colleagues have generated (Antal et al.,
2014). This study should serve as a model
for how other multimodular enzymes or
complexes may function.
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